

Under the auspices of:

Ministero della Salute



Istituto Superiore di Sanità



**FEDERCHIMICA
ASSOBIOTEC**
Associazione nazionale per lo sviluppo
delle biotecnologie



FOURTH WORKSHOP ON DRUG PRICING

SCIENTIFIC BOARD

Pier Luigi Canonico
Armando Genazzani
Claudio Jommi

ROME

MAY 17th | 18th, 2018

Under the auspices of:

Ministero della Salute



Istituto Superiore di Sanità



OBJECTIVE

Achieving a multistakeholder work table discussing about issues related to drugs pricing, focusing on innovation, early access programs, ATMPs and the impact on NHS of chronic diseases and their management.

Experts of international level will be part of the faculty to generate a between-countries comparison.

SESSION

SESSION I

ATMPs: research, access and regulatory aspects

SESSION II

Early access programs (EAPs) across Europe

SESSION III

Innovation – How to measure and reimburse innovation:
one year of experience with the new AIFA criteria

SESSION IV

The management of chronic diseases

THURSDAY, MAY 17th, 2018

13:45 Registration

14:00 Introduction
Pier Luigi Canonico
Armando Genazzani
Claudio Jommi

14:15 Lecture
AIFA strategy in pricing management
Mario Melazzini

SESSION I

ATMPs: RESEARCH, ACCESS AND REGULATORY ASPECTS

Chairperson: **Pier Luigi Canonico**

14:45 Lecture
The future of gene therapies and the role of public-private partnerships
Michela Gabaldo

15:15 ATMPs: state of the art in Italy
Elena Paola Lanati

15:35 ATMPs momentum: Biotech Industry point of view
Maria Luisa Nolli

15:55 Discussion

16:15 *Break*

THURSDAY, MAY 17th, 2018

SESSION II
EARLY ACCESS PROGRAMS (EAPS) ACROSS EUROPE

Chairperson: **Claudio Jommi**

- 16:30 The Italian ways for EAPs
Claudio Jommi
- 17:00 Tools and experience from the France HCS
Bernard Avouac (France)
- 17:30 Tools and experience from the Spanish HCS
Oriol De Solà-Morales Serra (Spain)
- 18:00 Tools and experience from the UK NHS
Hayden Holmes (UK)
- 18:30 Question time
- 19:00 Market Access Award prize-giving ceremony
- 19:30 Prize-giving ceremony cocktail and conclusion



FRIDAY, MAY 18th, 2018

SESSION III
INNOVATION – HOW TO MEASURE AND REIMBURSE INNOVATION:
ONE YEAR OF EXPERIENCE WITH THE NEW AIFA CRITERIA

Chairperson: **Pier Luigi Canonico**

- 9:00 Lecture
Criteria for the assessment of innovation: one year experience
Patrizia Popoli
- 9:30 Discussion
How to measure and reimburse innovation: one year of experience
with the new AIFA criteria
Armando Genazzani
Antonio Messina
Chiara Moroni
Patrizia Popoli

10:30 Question time

11:00 *Break*

SESSION IV
THE MANAGEMENT OF CHRONIC DISEASES

Chairperson: **Armando Genazzani**

- 11:15 Lecture
National Chronic Disease Plan and its implementation at National and Regional Level
Paola Pisanti

A light blue background featuring a detailed white line map of Rome, showing the city's streets and the Tiber River. A thin red horizontal line is positioned near the top of the page.

FRIDAY, MAY 18th, 2018

11:45 Discussion
The management of chronic diseases
Nello Martini
Aldo P. Maggioni
Francesca Patarnello
Paola Pisanti
Paolo Schincariol

12:45 Question time

13:30 Conclusion

SCIENTIFIC BOARD



PIER LUIGI CANONICO

**PROFESSOR OF PHARMACOLOGY,
UNIVERSITA' DEL PIEMONTE ORIENTALE**

Pier Luigi Canonico, MD and Specialist in Endocrinology and Metabolic Diseases, became Full Professor of Pharmacology at the Faculty of Medicine and Surgery at the University of Pavia in 1990; in 1999 he moved as Professor of Pharmacology and Pharmacotherapy to the Faculty of Pharmacy of the Università del Piemonte Orientale University in Novara. He was Chairman of the Department of Chemical, Nutritional, Pharmaceutical and Pharmacological Sciences (DISCAFF) from 2000 to 2008, Vice Dean of the Faculty from 2008 to 2009 and Dean from 2009 to 2011, Member of the Board of Directors of the University (2000-2001); actually he is also Member of the Senato Accademico (since 2002). From 2012 Prof. Canonico is Chairman and Dean of the Department of Pharmaceutical Sciences. He was the CEIMS Director from 2012 to 2013, and CEIMS Member of the Board since 2014.

Professor Canonico is member of several national and international scientific societies: among these, the Italian Society of Pharmacology (Councilor for 10 years and President from 2011 to 2013) and the Italian Society of Neuropsychopharmacology (Member of the Council since 2006). Among his extra-academic assignments, Member of the Commissione Unica del Farmaco (CUF) (Commission for Drug Approval and Reimbursement) of the Italian Ministry of Health (2001-2003), Vice-president of the Ethical Committee of the Institute for Neurological Research Casimiro Mondino (2006-2010), Member of the Scientific Group for Innovative Pharmacology (Biological Drugs) of the Presidenza del Consiglio dei Ministri (2008-2010), Member of the Regional Committee for the Organization of the Regional Network for Pain Therapy (Regione Piemonte). He is incoming President of ISPOR Italy Rome Chapter.

Prof. Canonico research includes several areas in the field of neuropsychopharmacology, neuroendocrinology, neurobiology, cancer therapy, pharmacogenetics/genomics and issues concerning biotechnology drugs. He is the author of over 200 publications on international journals.



ARMANDO GENAZZANI

**PROFESSOR OF PHARMACOLOGY,
UNIVERSITA' DEL PIEMONTE ORIENTALE**

Graduated in Medicine and Surgery at the University of Catania in 1993.

He then spent several years in Oxford, Zurich and Cambridge, working mainly on Ca²⁺-signalling and signal transduction in health and disease. In Cambridge, he was appointed University Lecturer at the Department of Pharmacology and Official Fellow of Clare Hall.

Since 2003 he is Professor of Pharmacology at the Università del Piemonte Orientale, and was appointed full professor in 2011.

His research still focuses on the role of signal transduction in health and disease, including Alzheimer's disease and oncological disorders, as well as on pharmacogenetics. He has authored over 150 publications on international journals.

He has also grown an interest in scientific, regulatory and market access-related issues in the pharmaceutical sector. In this area, along with Professor Canonico and Professor Jommi, he organizes a Master in "Regulatory Affairs and Market Access" at the Department of Pharmaceutical Sciences in Novara, is an expert since 2014 of the WHO "International non-proprietary names (INN) Committee" and is a member since 2015 of the "Commissione Tecnico-Scientifica" of the Italian Medicines Agency.

From 2013 to 2015 he was an elected member of the Board of the Italian Society of Pharmacology.

SCIENTIFIC BOARD



CLAUDIO JOMMI

ASSOCIATE PROFESSOR OF MANAGEMENT AT THE DEPARTMENT OF PHARMACEUTICAL SCIENCES, UNIVERSITA' DEL PIEMONTE ORIENTALE

Claudio Jommi is Associate Professor of Management at the Department of Pharmaceutical Sciences, University of Novara. He is also Scientific Director of the Pharmaceutical Observatory and Coordinator of the Health Policy Area at Cergas (Centre for Research on Health and Social Care Management), SDA Bocconi University, and Professor at Bocconi School of Management, Public Management and Policy Department, where he Coordinates the Specialisation in Pharmaceuticals and Medical Technologies, Master in International Health Management Economics and Policy (Mihmep).

He has been visiting professor at Essec Business School, Cergy (Paris), at the Herivan K. Haub School of Business, St Joseph University, Philadelphia (USA), at the Andrija School of Public Health, Zagreb and the University of Claude Bernard Lyon 1 (European Market Access University Diploma). His research activity is focused on Pharmaceutical Economics, Policy and Management, Health Technology Assessment and Decision Making in Health Care.

He has published in many international and national journals, including Drug Design Development and Therapy, European Journal of Health Economics, Health Policy, International Journal of Health Planning and Management, Journal of Medical Marketing, Pharmacoeconomics, PLOS Neglected Diseases, Public Money and Management and Social Science and Medicine.



BERNARD AVOUAC

MD CONSULTANT MARKET ACCESS AND REIMBURSEMENT, C2A

Consultant in market access and reimbursement for several years. Earlier in his career he worked as a Consultant rheumatologist at the Hospital Henri Mondor (Creteil — France).

He is also a visiting professor of epidemiology and public health at the Université de Liège.

He has published several high impact manuscripts in the fields of pharmacology and health economy. He was an active member of several drug appraisal committees at the Agence du Médicament and at the AFSSAPS in France. As President of the Transparency Committee in France, he provided advice to the Ministry of Health and Social Affairs for drug listing and pricing. He was also a member of the Medical Device reimbursement committee at the HAS as representative of Device Industry (SNITEM).



ORIO DE SOLÀ-MORALES SERRA

MD, MSC PHD HITT (HEALTH INNOVATION TECHNOLOGY TRANSFER), BARCELONA

I have built a career in the planning, policy and decision-making environment, participating not just in the micro management, but also being deeply involved on the meso and macro policy areas. I have been a policy advisor to 2 Ministries of Health.

I have held managing positions in healthcare planning and hospital management, and have been CAHTA's (Regional HTA) Director from 2007 to 2011. I have served as Innovation Director in Sagessa, a University Hospital trust, dealing with drug and devices portfolio, technology purchase and managed entry schemes. I've been involved in venture capital and start-ups.

In 2011 I founded HITT, a biotech consultancy specialised in Market Access and Technology Transfer.

I am an MD specialised in Internal Medicine. I earned an MSc from the London School of Economics and Political Science (LSE) and the London School of Hygiene and Tropical Medicine (LSHTM) and a PhD from Universitat Rovira I Virgili (URV).



MICHELA GABALDO

HEAD, ALLIANCE MANAGEMENT & REGULATORY AFFAIRS, FONDAZIONE TELETHON, MILAN

Michela Gabaldo is Head, Alliance Management & Regulatory Affairs at Fondazione Telethon in Milan, Italy where she joined in 2011. As Head of Alliance Management she was responsible for the execution of the first strategic Alliance of Telethon/OSR with GSK managing gene therapy projects at different stage of development ranging from preclinical, to clinical, to Registration & Market Access. With her capability to work in a matrix, she paved the way for the very first ex-vivo gene therapy (Strimvelis) to move from clinical trial to market, ensuring alignment and understanding between stakeholders from different areas and entities. Through her collaborators she's also responsible for the execution of the other strategic alliances established by Telethon at both the internal Institutes (i.e., SR-TIGET and TIGEM).

Michela is also Head of Regulatory Affairs at Fondazione Telethon supporting internal Institutes through the clinical development. After graduation in Pharmaceutical Chemistry and Technology from the Padua University, she joined GSK in 2001 where she was involved in drug development working in Clinical Operations and CMC Regulatory Affairs areas. She then granted a Master Degree in Regulatory Affairs and Market Access for NCE and Biopharmaceutical products from Novara University in 2010. Winner of 2017 edition of TopRA Award in the Future category, Michela offers up to date knowledge of the most recent regulation in ATMPs and is frequently invited as speaker at international events on the subject. She's currently a member of the IRDIRC Scientific Committee.



HAYDEN HOLMES

**SENIOR RESEARCH CONSULTANT,
YORK HEALTH ECONOMICS CONSORTIUM**

Hayden Holmes has a Post Graduate Diploma in Public Health Medicine from the University of Otago in New Zealand. Hayden is experienced in developing economic models, research and critical appraisal. Prior to joining YHEC, Hayden lived and worked in New Zealand, working in health economics and health policy. Hayden has spent six years working for Pharmac, which is the government agency responsible for making decisions on which medicines, vaccines, hospital medical devices, cancer and haemophilia treatments are publicly funded in New Zealand. Hayden spent two years as a policy advisor on a medical devices project establishing the policies and processes for Pharmac to manage the procurement of all medical devices into publically funded hospitals in New Zealand. Hayden worked as a health economist at Pharmac and was heavily involved in the prioritisation process for choosing which new medicines should be publically funded. This involved working closely with the Pharmac contract negotiators to establish innovative methods to get the most value from the NZ pharmaceutical budget. Hayden now works at York Health Economics Consortium as a senior research consultant. He works on a range of projects from individual pharmaceuticals to wider public health initiatives including work for the NHS and Public Health England. Hayden has previous experience in the Royal New Zealand Air Force, where he was an NCO in logistics where his experiences included peace keeping in Bougainville Island and re-supply missions to Antarctica. He is also a keen trail runner and has completed a number of ultramarathons.



ELENA PAOLA LANATI

**MANAGING DIRECTOR,
MA PROVIDER, MILAN**

Paola has worked for years as a manager in pharmaceutical companies (AstraZeneca, BMS, UCB, P&G), occupying the position of Business Unit Director, first in Primary Care and then in Specialty Care. In her career, she managed issues of market access (IPP, oncology, CNS) and dossiers of price negotiation. In 2010 she founded first 3P Solution and then MA Provider for which she won a selection in Lombardia Region for the launch of new companies, thanks to a project on the pricing of new drugs.


Businesswoman and Mom, Paola runs a growing team of 30 people, is passionate about pricing and patient advocacy, and loves to make her own contribution and to stimulate the challenges of our healthcare system. Founder and secretary of Ispor Italy Rome Chapter.



ALDO P. MAGGIONI

**MD, FESC
DIRECTOR, ANMCO RESEARCH CENTER, FLORENCE**


Aldo Maggioni received his medical degree from the Milan University and performed the cardiology residency at the Padua University. He is a member of the Steering Committee of the GISSI studies and Director of the ANMCO Research Center in Florence. Since 2010, he is Scientific Coordinator of the EURObservational Research program of the European Society of Cardiology. He served as a member of Executive/Steering Committees, Event Evaluation Committees, Data Monitoring Committees of more than 60 controlled clinical studies conducted in the cardiovascular and metabolic areas. He is author of more than 500 peer-reviewed papers and included in the list of highly cited researchers over the last 15 years (2003-2017) by Thomson Reuters.



NELLO MARTINI

DIRECTOR, DRUGS&HEALTH, ROME

Nello Martini graduated in Pharmacy and specialized in Clinical Pharmacology. From 1973 to April 1998 directed the pharmacy of the Policlinico Borgo-Rome in Verona. From May 1998 to June 2004 he was General Director of Drugs and Medical Devices of the Ministry of Health. Later held the position of General Director of the Italian Drugs Agency (AIFA) until June 2008, and was a member of the Board of Directors of the EMA. Currently holds the position of Director of Drugs & Health - Rome. He carried out training courses in France and in the United States and is author of over 150 publications including books and scientific articles.



ANTONIO MESSINA

VICE PRESIDENT OF FARMINDUSTRIA, CHAIRMAN OF THE BOARD OF DIRECTORS AND MANAGING DIRECTOR OF MERCK SERONO SPA, ROME

Antonio Messina is the Chairman of the Board of Directors and Managing Director of Merck Serono S.p.A. He graduated in Biology at the University "La Sapienza" of Rome and he completed his training programme with a MBA course in "Strategic Executive Program" at Babson College of Boston, a Finance course for Executive at INSEAD of Milan and Biopharma Breakthrough 2008 at London Business School. In 2016 the University of Bari awarded him the Honoris Causa Degree in Chemistry and Pharmaceutical Technologies. In April 1999 he was hired as a Director of Neurological Line in Merck Serono S.p.A and in 2003 he was appointed Country Manager of Greece and then in 2006 General Manager of both Greece and Italy. Before starting his experience in Merck, he played different roles at Bayer and Rhone Poulenc Rorer. In this last company, he was at first Product Manager in Oncology in UK and then Marketing Manager in Italy. Since 2014 he has been a Member of the Farmindustria Committee and from September 2017 was appointed Vice President of Farmindustria.



MARIO MELAZZINI

GENERAL DIRECTOR, AIFA, ROME


Mario Melazzini, medical doctor, specialized in general hematology and clinical laboratory, and researcher in the field of hematology-oncology, is currently Chairman of the Board of the Italian Medicines Agency (AIFA).

He was previously Director of the Oncology DH of the Scientific Institute for Research, Hospitalization and Healthcare "Fondazione Salvatore Maugeri" in Pavia. He was also contract professor at the University of Pavia - Faculty of Medicine and Surgery.

He was Director of the complex structure of continuity of care hospital-territory of the Niguarda Ca 'Granda hospital in Milan and Director of Health Planning and Development of Lombardy Regional Plans. He has covered the role of Councillor for Health, Councillor for Industry, Research and Innovation, and Councillor for Universities, Research and Open Innovation of the Lombardy Region. He is member of the Technical Health Committee of the Ministry of Health and Chairman of the Commission for Health Research of the Ministry of Health (Section C). He is the President of Aurora Onlus Foundation, belonging to the "Nemo Sud" Clinical Centre at the Azienda Ospedaliera Universitaria Policlinico 'G. Martino' in Messina and Scientific Director of the Clinical Center of Serena NeMo Onlus Foundation at the Niguarda Hospital in Milan.

He was Chairman of the Ministerial Commission on Neuromuscular Diseases at the Ministry of Health, where he was responsible for organizing and coordinating activities, and Member of the Working Group on Rehabilitation, in charge of updating the guidelines for rehabilitation activities, in cooperation with Italian Regional Authorities. He was the Scientific Coordinator and Head of the Technical Discussion Group for Policies for People with Disabilities of the Lombardy Region. He was the National President of both AISLA Onlus (Italian Association for Amyotrophic Lateral Sclerosis) and ArISLA Italian Foundation for research on Amyotrophic Lateral Sclerosis. He was also National Secretary of the Italian Federation for the Overcoming of Handicaps (FISH).

He has published numerous scientific articles and he is author of several books related to his experience both as a doctor and as a patient.



CHIARA MORONI

MARKET ACCESS LEAD BRISTOL-MYERS SQUIBB, ROME

Chiara Moroni is currently Market Access Lead in Bristol-Myers Squibb since 2016. This role includes responsibility for government affairs, third parties engagement and communication activities.


Prior to this position, she was Government & Public Affairs Lead.

Before joining Bristol-Myers Squibb, she was responsible for the government affairs in the Noesis Agency working on behalf of national & foreign public and private companies.

At the age of 26 she was elected at the "Camera dei Deputati". She was the youngest parliamentarian of the XIV Legislature; she had the mandate for three legislatures until 2013.

During her parliamentary activity she gained a strong expertise in the regulated market issues, such as the pharmaceutical and energy ones. She started important legislative action as a member of "Commissione Bilancio" and "Commissione Salute della Camera".

From 1999 to 2001 she conducted basic research activity in the field of neuroscience as a research-fellow at the Department of Pharmacology of Brescia University.



MARIA LUISA NOLLI

MEMBER OF THE BOARD OF ASSOBIOTEC AND EUROPABIO

Maria Luisa is co-founder and CEO of NCNbio, a start up company, for the Industrial Technology Transfer in the field of biotechnology. Maria Luisa was the founder and former CEO of Areta International, a biotech company focused on the development and production of innovative biodrugs and advanced therapy medicinal products and she was the site manager of the company from 2000 to 2012. Maria Luisa is also a co-founder of two university spin off, Hope and Skin Squared, respectively with the Milano University and Modena University. Maria Luisa brought to all these companies her multi years experience in cell biology and immunology, matured as scientist and team leader in multinational companies of Dow Chemical as Dow Lepetit, Merrell Dow, Marion Merrell Dow e Hoechst Marion Roussel. Maria Luisa (ex alumna of Collegio Ghislieri in Pavia), received her doctoral degree in Biological Sciences from the University of Pavia (1977). She had a doctoral fellow at the Université Libre de Bruxelles, and a Post Doctoral Fellow at the Istituto di Medicina del Lavoro, University of Pavia and at the International Institute of Genetics and Biophysics (CNR Naples). From 2008 Maria Luisa is member of the board of Assobiotech and delegate to Europabio board. From June 2014 is member of the board of AFI (Associazione Farmaceutici dell'Industria) as representative of the biotech sector and AIRI (Associazione Italiana Ricerca Industriale) as expert of red biotech. From 2015 Maria Luisa is president of Women & Technology Association and member of the Board. In 2007 she received the "Premio Piazza Mercanti" from the Milan Chamber of Commerce. In 2009 is one of the 100 profiles of the volume dedicated to Milan of "The protagonists: women who make Italy". In 2012 she received the "Premio "Rosa Camuna" from Regione Lombardia for innovative entrepreneurship. She was professor at the University of Milano Bicocca (2001-2008) and Bari (2004-2011) and from February 2016 she is professor at Pavia University of Biochimica Industriale course. Maria Luisa is author and co-author of more than 60 publications and 11 patents.



FRANCESCA PATARNELLO

VICE PRESIDENT MARKET ACCESS & GOVERNMENT AFFAIRS, ASTRAZENECA ITALIA, MILAN

Francesca Patarnello is, since March 2017, Vice President Market Access & Government Affairs, AstraZeneca Italia. Degree in Statistics and Economics, began his career in Farmitalia Carlo Erba, passing successively from Fidia to GlaxoSmithKline. Before AstraZeneca she spent three years as Value and Access Director in Amgen, working to make accessible to patients the innovative pipeline. Before moving to the Market Access, she plays a number of roles in medical science, including HTA Director and Scientific Director and Quality. Member of several working groups, Francesca currently sits on the Board of Directors of SIHTA (Society of Health Technology Assessment) and also held a series of academics positions at the University of Bologna, Catania, Novara, Padova and Verona. She is co-author of numerous publications regarding innovation of drugs, on HTA and on market access.



PAOLA PISANTI

**COORDINATOR OF THE WORKING GROUP CHRONICITY,
MINISTRY OF HEALTH, ROME**

Paola Pisanti graduated in Medicine and Surgery at the University of Naples on the 29th July 1976 with full marks (110/110) and was Doctor of General Medicine from November 1978 until 31st December 1992.

She has been in charge in Healthcare Services management at Ministry of Health and she is currently an expert in chronic diseases at Ministry of Health.

She is the President of the National Commission for Diabetes, the Coordinator of the working group for osteoporosis and densitometric research access criteria, the Coordinator of chronic diseases working groups and the coordinator of Commission for the National Plan of Chronicity. She has carried out and still carries out teaching activities within universities.

She has participated as a speech giver at numerous national and international conventions and congresses; she is the co-author of several publications on national and international scientific journals.



PATRIZIA POPOLI

**HEAD, NATIONAL CENTER OF DRUG RESEARCH AND EVALUATION,
ISTITUTO SUPERIORE DI SANITÀ, ROME**

Patrizia Popoli obtained a degree in Medicine and Surgery at the Università degli Studi in Perugia. She majored in neurological clinic at the Università degli Studi in Perugia. Currently, she is leader of research at the Department of Pharmacology at Istituto Superiore di Sanità, Director of National Center for Drug Research and Evaluation and member of the Committee for the evaluation of admission to Phase I clinical trials.

She has been for many years permanent substitute of the President of Istituto Superiore di Sanità in the Scientific and Technical Committee of AIFA and is currently President of this Committee. In the field of research, Patrizia is interested in Central Nervous System Pharmacology.

She is a member of national and international scientific societies and author of several publications. Furthermore, she performs numerous regulatory activities in the pharmaceutical sector.



PAOLO SCHINCARIOL

DIRECTOR OF THE PHARMACEUTICAL ASSISTANCE "ASUITS", TRIESTE

Paolo Schincariol graduated in Pharmacy at the University of Trieste. He specialized in Hospital Pharmacy at the University of Padova and graduated in Information Management Master for directors of pharmaceutical departments of the SSN-Florence.

Currently, he is the director of the inter-company function of the pharmaceutical department at the hospital corporation integrated with the university hospital of Trieste.

He is a Member of the Technical and Scientific Committee AIFA D.M., a Member of the Regional Committee for Ethics, a Member of the Regional Pharmaceutical Committee and a Member of the Regional Work-Group for the Implementation of the GRADE Method in Onco-Haematology.

He is a Professor of Critical Evaluation of Literature at the Hospital Corporation integrated with the Hospital University of Udine Academic.

He is the author of public interventions and academic- research papers.



MA AWARD

MARKET ACCESS AWARD 2018


The Market Access Award 2018, at its fourth edition, wants to reward the best partnership between private companies and public institutions aimed to optimize the patient care access through innovative solutions.

The evaluation criteria to assign the prize will be:

- ✓ scientific value of the project
- ✓ benefit to patients
- ✓ innovation and added value in the interaction between private and public
- ✓ replicability of the project

The judging board will be composed by:

- **Pier Luigi Canonico**
Director of the Department of Pharmacological Sciences, Università degli Studi del Piemonte Orientale
- **Ivan Gardini**
President of EpaC Onlus
- **Antonio Gaudioso**
Secretary-General of CittadinanzAttiva
- **Armando Genazzani**
Full Professor of Pharmacology, Università degli Studi del Piemonte Orientale
- **Claudio Jommi**
Associate Professor at the Department of Pharmacological Sciences, Università degli Studi del Piemonte Orientale; Scientific Director Drugs Observatory, Cergas, Università Bocconi; President of the Italian Association of Health Economics
- **Elena Paola Lanati**
Managing Director, MA Provider, Milan
- **Franco Perrone**
Director Clinical Trials Unit National Cancer Institute of Naples





via Vincenzo Monti 3
20123 Milano
tel +39 02 89096682
fax +39 02 89098927
e-mail | info@maprovider.com

piazza San Salvatore in Lauro 10
00186 Roma
tel | fax +39 06 68806614
e-mail | info.roma@maprovider.com

web | www.maprovider.com

